Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 19,019 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 19,019 shares of Arcus Biosciences stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $20.19, for a total value of $383,993.61. Following the transaction, the president directly owned 1,169,214 shares of the company’s stock, valued at approximately $23,606,430.66. The trade was a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Arcus Biosciences Stock Down 0.7%

Shares of NYSE RCUS opened at $20.15 on Friday. The stock has a market cap of $2.14 billion, a PE ratio of -5.86 and a beta of 0.77. The business has a fifty day moving average of $13.76 and a two-hundred day moving average of $10.65. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $22.11. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.50 and a current ratio of 3.65.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.06. The company had revenue of $26.00 million during the quarter, compared to analysts’ expectations of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The business’s revenue was down 45.8% on a year-over-year basis. During the same period last year, the business earned ($1.00) earnings per share. As a group, equities research analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RCUS has been the subject of a number of analyst reports. HC Wainwright lifted their price objective on Arcus Biosciences from $24.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday. Wall Street Zen raised Arcus Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th. Wells Fargo & Company lifted their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group increased their price objective on shares of Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Arcus Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $28.44.

Institutional Investors Weigh In On Arcus Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Woodline Partners LP raised its holdings in Arcus Biosciences by 45.5% during the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock worth $40,249,000 after purchasing an additional 1,603,367 shares during the last quarter. Gilead Sciences Inc. raised its holdings in Arcus Biosciences by 4.5% during the 1st quarter. Gilead Sciences Inc. now owns 31,424,760 shares of the company’s stock worth $246,684,000 after purchasing an additional 1,363,636 shares during the last quarter. Vanguard Group Inc. raised its holdings in Arcus Biosciences by 24.1% during the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after purchasing an additional 1,298,584 shares during the last quarter. RA Capital Management L.P. bought a new stake in Arcus Biosciences during the 1st quarter worth about $8,920,000. Finally, Wellington Management Group LLP bought a new stake in Arcus Biosciences during the 1st quarter worth about $8,500,000. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.